Sareum Holdings PLC
SAR
Company Profile
Business description
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.
Contact
Langford Arch, London Road
Unit 2a, Pampisford
CambridgeCambridgeshireCB22 3FX
GBRT: +44 1223497700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
5
Stocks News & Analysis
stocks
After Earnings, is Alphabet stock a buy, a sell, or fairly valued?
With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
stocks
Moated ASX share crashes amid weak trading update
Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,015.40 | 48.70 | 0.54% |
| CAC 40 | 7,857.36 | 56.48 | 0.72% |
| DAX 40 | 24,217.37 | 247.01 | 1.03% |
| Dow JONES (US) | 44,632.99 | 204.57 | -0.46% |
| FTSE 100 | 9,136.32 | 54.88 | 0.60% |
| HKSE | 25,225.09 | 299.36 | -1.17% |
| NASDAQ | 21,098.29 | 80.29 | -0.38% |
| Nikkei 225 | 40,645.44 | 29.11 | -0.07% |
| NZX 50 Index | 12,855.97 | 80.44 | -0.62% |
| S&P 500 | 6,370.86 | 18.91 | -0.30% |
| S&P/ASX 200 | 8,756.40 | 51.80 | 0.60% |
| SSE Composite Index | 3,614.07 | 4.36 | 0.12% |